Functional drug susceptibility testing based on biophysical measurements predicts patient outcome in glioblastoma patient-derived neurosphere models
M. A. Stockslager, S. Malinowski, M. Touat, J. C. Yoon, J. Geduldig, M. Mirza, A. S. Kim, P. Y. Wen, K.-H. Chow, K. L. Ligon, S. R. Manalis
Using biophysical assays on glioblastoma patient-derived neurosphere models, the study finds that ex vivo drug susceptibility testing predicts patient survival with similar accuracy to MGMT promoter methylation.
bioRxiv · Aug 5, 2020 · PreprintCancer Biology